Frailty in scarring lung disease: a study
Part of Brain & nervous system clinical trials.
This study looks at how frailty (a state of being more vulnerable to health problems) affects people with scarring lung diseases. It aims to understand if frailty can help predict how the disease will progress and how treatments might be adjusted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 66 years or older.
- You have a type of lung scarring disease (called fibrosing interstitial lung disease) as diagnosed by your doctor.
- You have a scheduled visit at a hospital clinic or day hospital.
- You speak French.
- You are not under legal guardianship or curatorship, and you don't have memory or thinking problems that would make it hard to answer questions.
- Your recent CT scan does not show a specific early scarring pattern called 'early UIP'.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with COPD or ILD who also show signs of frailty. It aims to understand how frailty and muscle loss (sarcopenia) affect their care and use of medical resources over time.
This study looks at how frailty affects the course of chronic diseases and how chronic diseases affect frailty. It may help understand aging-related conditions better.
This trial looks at ways to help “frailty” (low strength and resilience) in people staying in intensive care units. It mainly enrolls adults who expect to be in the ICU for more than 24 hours, and it tries to avoid people whose mobility problems have other causes.
This study looks at proteins in the blood to understand muscle loss (sarcopenia) in people with chronic lung disease. It aims to find better ways to detect and manage this condition.
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
Hear when a new Sarcopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.